FOXO Technologies Inc., listed on NYSE American under the symbol FOXO, has announced on June 14, 2024, that it received a notice of noncompliance from NYSE Regulation due to an outstanding balance of listing fees. The notice, dated June 10, 2024, indicated that the company had until June 7, 2024, to make the payment to avoid noncompliance procedures. Despite missing the initial deadline, FOXO Technologies has since paid the fees and is taking steps to regain compliance with NYSE American's continued listing standards. The company, which specializes in biotechnology for health and longevity, is now subject to the procedures outlined in Section 1009 of the Company Guide. FOXO Technologies must submit a written response by June 17, 2024, detailing actions to resolve the delinquency. Failure to do so...Show More

FOXO Technologies Inc., listed on NYSE American under the symbol FOXO, has announced on June 14, 2024, that it received a notice of noncompliance from NYSE Regulation due to an outstanding balance of listing fees. The notice, dated June 10, 2024, indicated that the company had until June 7, 2024, to make the payment to avoid noncompliance procedures. Despite missing the initial deadline, FOXO Technologies has since paid the fees and is taking steps to regain compliance with NYSE American's continued listing standards. The company, which specializes in biotechnology for health and longevity, is now subject to the procedures outlined in Section 1009 of the Company Guide. FOXO Technologies must submit a written response by June 17, 2024, detailing actions to resolve the delinquency. Failure to do so or to make progress towards payment as accepted by NYSE may lead to delisting proceedings. The company has confirmed receipt of the notice and plans to present a compliance plan, with the intention to regain compliance. However, there is no assurance that FOXO Technologies will meet the listing standards again. The company's interim CEO, Mark White, expressed regret over the delinquency, attributing it to short-term capital allocation strategies and recent planned acquisitions. The company believes these acquisitions will contribute to future cash flow.